Aclaris Therapeutics Files 8-K

TL;DR

ACRS filed an 8-K on 7/16 for a material definitive agreement.

AI Summary

On July 16, 2024, Aclaris Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located at 701 Lee Road, Suite 103, Wayne, PA 19087.

Why It Matters

This 8-K filing indicates a significant event for Aclaris Therapeutics, Inc., potentially involving a material definitive agreement that could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce significant business and financial risks or opportunities, the details of which are not fully disclosed in this initial filing.

Key Players & Entities

• Aclaris Therapeutics, Inc. (company) — Registrant
• July 16, 2024 (date) — Date of earliest event reported
• 701 Lee Road, Suite 103 Wayne, PA 19087 (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.00001 — ange on which Registered Common Stock, $0.00001 par value ACRS The Nasdaq Stock Mar
• $26.5 million — Company received an upfront payment of $26.5 million and is eligible to receive up to an add
• $5.0 million — eligible to receive up to an additional $5.0 million based on the achievement of certain sal

Filing Documents

• acrs-20240716x8k.htm (8-K) — 40KB
• acrs-20240716xex99d1.htm (EX-99.1) — 10KB
• acrs-20240716xex99d1001.jpg (GRAPHIC) — 11KB
• 0001558370-24-009853.txt ( ) — 188KB
• acrs-20240716.xsd (EX-101.SCH) — 3KB
• acrs-20240716_lab.xml (EX-101.LAB) — 16KB
• acrs-20240716_pre.xml (EX-101.PRE) — 10KB
• acrs-20240716x8k_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On July 16, 2024, Aclaris Therapeutics, Inc. (the " Company ") and OCM IP Healthcare Portfolio LP, an investment vehicle of OMERS, entered into a royalty purchase agreement (the " Agreement ") pursuant to which the Company sold to OMERS a portion of its future royalty payments and the remaining anniversary milestones associated with the Company's existing license to Eli Lilly and Company (" Lilly ") relating to OLUMIANT (baricitinib) for the treatment of alopecia areata. Under the terms of the Agreement, the Company received an upfront payment of $26.5 million and is eligible to receive up to an additional $5.0 million based on the achievement of certain sales milestones for OLUMIANT in 2024. In exchange, OMERS acquired a portion of the royalty payable by Lilly to the Company for worldwide net sales of OLUMIANT for the treatment of alopecia areata from April 1, 2024 through the remainder of the royalty term under the Company's license agreement with Lilly, and 100% of the remaining anniversary milestone payments payable by Lilly to the Company under the license agreement. The Agreement contains customary representations, warranties, covenants, and indemnification provisions. The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On July 16, 2024, the Company issued a press release announcing entry into the Agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act ") or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated July 16, 2024. 104 The cover page from Aclaris Therapeutics, Inc.'s Form 8-K filed on July 16, 2024, formatted in Inline XBRL. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACLARIS THERAPEUTICS, INC. By: /s/ Kevin Balthaser Date: July 16, 2024 Kevin Balthaser Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR